Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two full years alongside radiation can meaningfully reduce the chance the ...

Scientists have developed a fully human antibody that halted the growth and spread of aggressive prostate cancer in preclinical research. Although more testing is needed, the drug’s unusual mechanism ...

An NHS trial over 10 years followed nearly 3,500 men who received focal therapy, a less invasive treatment.

Researchers have developed a fully human antibody that suppressed tumor growth and metastatic spread in preclinical models of ...

May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and ...

Montell Jordan confirmed his cancer has returned and spread to his lymph nodes nearly a year after prostate removal surgery. Montell Jordan delivered a sobering health update during an appearance on ...

(Reuters) - Use of Xtandi in early stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone, study ...

A new and important genetic discovery, which sheds light on how prostate cancers develop and spread, has been made by an international research team led by scientists at The University of Nottingham.

Researchers at the University of British Columbia have identified a new form of hereditary prostate cancer that, while rare, ...